艾塞那肽周制剂对2型糖尿病患者颈动脉粥样硬化的影响:18个月随机安慰剂对照研究
这项双盲实用性随机试验将163例2型糖尿病患者按2:1随机分为艾塞那肽组(n=109)与安慰剂组(n=54),用3T多对比MRI在9个月和18个月时测量颈动脉斑块体积与成分变化。结果显示艾塞那肽改善HbA1c及空腹、餐后血糖,但斑块体积变化与安慰剂组无差异,斑块成分、体重、血压、甘油三酯及内皮功能变化亦无组间差异。
要点
- 艾塞那肽周制剂未改变颈动脉斑块体积或成分的进展。
- 艾塞那肽显著降低HbA1c及空腹、餐后血糖。
- 短期抗动脉粥样硬化作用可能不是GLP-1RA心血管获益的核心机制。
核心结论
- 每周一次艾塞那肽治疗最长18个月改善了空腹和餐后血糖控制,但未改变颈动脉斑块体积或成分的变化。
- 研究提示短期抗动脉粥样硬化效应可能不在GLP-1受体激动剂心血管获益中起核心作用。
研究设计与样本
- 双盲、实用性随机安慰剂对照试验,163例受试者按2:1随机分为艾塞那肽组(n=109)和安慰剂组(n=54)。
- 在第9个月和第18个月通过多对比3特斯拉MRI测量颈动脉斑块体积和成分变化。
- 在第3、9、18个月测量空腹及高脂餐后血浆葡萄糖、血脂和内皮功能反应。
主要发现
- 艾塞那肽降低HbA1c,与安慰剂相比估计差异为0.55%(P=0.0007)。
- 艾塞那肽降低空腹血糖(19 mg/dL,P=0.0002)和餐后血糖(25 mg/dL,P<0.0001)。
- 艾塞那肽组斑块体积平均(SD)变化为0.3%(2%),与安慰剂组的-2.2%(8%)无差异(P=0.4)。
- 艾塞那肽组斑块体积变化与HbA1c变化(r=0.38,P=0.0004)、体重及总体血浆葡萄糖变化(两者r=0.29,P=0.007)相关。
- 两组在斑块成分、体重、血压、空腹及餐后甘油三酯和内皮功能变化上无差异。
关键数值与推荐
- HbA1c与安慰剂相比的估计差异为0.55%(P=0.0007)。
- 空腹血糖降低19 mg/dL(P=0.0002),餐后血糖降低25 mg/dL(P<0.0001)。
- 斑块体积变化组间比较P=0.4。
- 斑块体积变化与HbA1c相关r=0.38(P=0.0004),与体重及总体血糖相关r=0.29(P=0.007)。
临床怎么用
- 对2型糖尿病患者使用艾塞那肽周制剂时,应以改善血糖控制为主要预期获益之一。
- 不应仅依据短期改善血糖或替代指标来预期颈动脉斑块进展的减缓。
- GLP-1RA的心血管获益机制可能不完全依赖短期抗动脉粥样硬化效应,仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) improved multiple proatherogenic risk factors and reduced cardiovascular events in recent clinical trials, suggesting that they may slow progression of atherosclerosis. We tested whether exenatide once weekly reduces carotid plaque progression in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a double-blind, pragmatic trial, 163 participants were randomized (2:1) to exenatide (n = 109) or placebo (n = 54). Changes in carotid plaque volume and composition were measured at 9 and 18 months by multicontrast 3 Tesla MRI. Fasting and post-high-fat meal plasma glucose and lipids, and endothelial function responses, were measured at 3, 9, and 18 months. RESULTS: Exenatide reduced hemoglobin A1c (HbA1c) (estimated difference vs. placebo 0.55%, P = 0.0007) and fasting and postmeal plasma glucose (19 mg/dL, P = 0.0002, and 25 mg/dL, P < 0.0001, respectively). Mean (SD) change in plaque volume in the exenatide group (0.3% [2%]) was not different from that in the placebo group (-2.2% [8%]) (P = 0.4). The change in plaque volume in the exenatide group was associated with changes in HbA1c (r = 0.38, P = 0.0004), body weight, and overall plasma glucose (r = 0.29, P = 0.007 both). There were no differences in changes in plaque composition, body weight, blood pressure, fasting and postmeal plasma triglycerides, and endothelial function between the groups. CONCLUSIONS: Exenatide once weekly for up to 18 months improved fasting and postprandial glycemic control but did not modify change in carotid plaque volume or composition. This study raises the possibility that short-term antiatherosclerotic effects may not play a central role in the cardiovascular benefits of GLP-1RAs.
引用
- Koska J, Migrino RQ, Chan KC, et al. The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study. Diabetes Care. 2021. PMID: 33495294. doi:10.2337/dc20-2014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。